Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case–control study

Wang, Fei; Zou, Zhirong; Dong, Yanjun; Gong, Yi; Zhang, Li; Chen, Xun; Sun, Tao; Yu, Hualin

doi:10.1042/bsr20160446

Cited by 19 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the cognitive implications of S100B are not limited to T2DM: studies have shown that this protein is involved in cognitive impairment in a variety of diseases, including cerebral small vessel disease and AD [9,48]. Cerebral small vessel disease (CSVD) is an age-related disease affecting the small blood vessels of the brain.…”

Section: Discussionmentioning

confidence: 99%

Levels of serum S100B are associated with cognitive dysfunction in patients with type 2 diabetes

Liu

et al. 2020

Aging

View full text Add to dashboard Cite

Objective: Previous studies have provided robust evidence that cognitive impairment exists in patients with type 2 diabetes. The predictive role of S100B in a variety of neurodegenerative diseases such as Alzheimer's disease, has been shown to be closely related to cognitive function. The purpose of this study was to investigate the correlation between serum S100B levels and cognitive function in type 2 diabetes patients. Results: The type 2 diabetes group scored lower than the healthy control group in all domains of cognitive function except language and attention, and the former group also had lower serum levels of S100B. Besides, serum S100B levels were lower in the type 2 diabetes patients with impaired cognition than in those with normal cognition. In addition, the moderate to severe cognitive impairment group had significantly lower levels than that in mild cognitive impairment group. After adjusting for confounding factors, serum S100B levels were positively correlated with cognitive function in type 2 diabetes patients. Conclusions: Serum S100B levels were positively correlated with cognitive function in type 2 diabetes patients with cognitive impairment. It is suggested that S100B may be involved in the occurrence and development of cognitive dysfunction in type 2 diabetes patients and play a protective role. Methods: The clinical data and biochemical indexes of ninety-six patients with type 2 diabetes and sixty-eight healthy subjects were collected. The levels of serum S100B were detected by enzyme-linked immunosorbent assay. Ninety-six type 2 diabetes patients were divided into a cognitive dysfunction group and a normal cognition group according to Mini-mental State Examination scores. To better understand the differences in various aspects of cognition, we used the Repeatable Battery for the Assessment of Neuropsychological Status scale for further evaluation. To study the relationship between serum S100B levels and cognitive impairment, the cognitive dysfunction group was divided into a mild cognitive impairment group and a moderate to severe cognitive impairment group for further study.

show abstract

Section: Discussionmentioning

confidence: 99%

Levels of serum S100B are associated with cognitive dysfunction in patients with type 2 diabetes

Liu

et al. 2020

Aging

View full text Add to dashboard Cite

show abstract

“…Davidson et al [ 18 ] showed that carrying the APOE- ε 4 allele was associated with an increased risk of vascular dementia. Treves et al [ 19 ] showed that the APOE- ε 4 allele frequency was highest in AD patients, followed by VCIND patients, and then the control group. Hsiung et al [ 20 ] showed that VCIND patients and APOE- ε 4 allele carriers are more common in advanced disease patients.…”

Section: Discussionmentioning

confidence: 99%

The Value of Brain Structural Magnetic Resonance Imaging Combined with APOE‐‐ε4 Genotype in Early Diagnosis and Disease Progression of Senile Vascular Cognitive Impairment No Dementia

Zhao

Yin

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Objective. To explore the value of brain structure magnetic resonance imaging combined with APOE-ε4 genotype in the early diagnosis and disease progression of elderly patients with vascular cognitive impairment no dementia (VCIND). Methods. The first stroke patients admitted to our hospital from March 2017 to December 2018 were collected, including 130 cases of vascular cognitive impairment no dementia (VCIND group) and 50 cases of the control group (NC group). The basic information of all subjects was recorded, and APOE-ε4 alleles of all subjects were detected. The neuropsychological test scale evaluated the cognitive psychology of the subjects, and they were scanned by multi-parameter MRI. After follow-up, VCIND patients were divided into the dementia group and the nondementia group. MRI scans were again performed, and the risk factors of VCIND patients developing dementia were analyzed. Results. Compared with the NC group, patients in the VCIND group had shorter years of education, more patients with hypertension, higher levels of homocysteine (Hcy), and lower cognitive ability. Patients with White Matter Volume (WMV), White Matter Hyperintensity (WMH), Lacunar Infarction (LI), elevated Fazekas scores, and APOE-ε4 gene carriers are more likely to develop VCIND. After 12 months of follow-up, compared with the nondementia group, the number of WMV, WMH, Fazekas scores, and APOE-ε4 gene carriers in the dementia group was significantly increased. In addition, the progression-free survival rate of APOE-ε4 gene carriers was significantly lower than that of nonAPOE-ε4 gene carriers. Conclusion. Years of education, hypertension, high levels of Hcy, elevated WMV, WMH, LI, and Fazekas scores, and carrying the APOE-ε4 gene are risk factors for VCIND in stroke patients. Craniocerebral structural MRI combined with APOE-ε4 genotype has a diagnostic role in the early diagnosis and disease progression of elderly patients with VCIND.

show abstract

“…The Mini‐Mental State Evaluation (Chinese version, full mark is 30) and Montreal Cognitive Assessment Scale (Chinese version, full mark is 30) were performed by specialised personnel of research team. According to the newly published diagnostic criteria and classification of postoperative neurocognitive dysfunction, 12 delayed postoperative neurocognitive recovery was defined as patient in whom scores decreased by more than or equal to 1 standard deviation from preoperative levels on one or two cognitive assessment scales 13‐15 …”

Section: Methodsmentioning

confidence: 99%

Association between the variability of cerebral oxygen saturation during cardiopulmonary bypass and delayed postoperative neurocognitive recovery in cardiac valve surgical patients: A pilot study

et al. 2020

View full text Add to dashboard Cite

Aims of the study The association between regional cerebral oxygen saturation (rSO2) and postoperative cognitive decline is controversial. In this study, we investigated the association between the real variability of regional cerebral oxygen saturation during cardiopulmonary bypass (CPB) and postoperative delayed neurocognitive recovery in patients undergoing heart valve surgery. Methods used to conduct the study A total of 71 patients who underwent cardiac valve surgery were enrolled in this study. Patients were assessed for cognitive function using the Mini‐Mental State Examination (MMSE) and the Montreal Cognitive Assessment Scale (MOCA) on the day before surgery and the 7th day after surgery. The real variability of regional cerebral oxygen saturation (rSO2), real variability of the brain bispectral index of EEG (BIS), real variability of mean arterial pressure (MAP) and body temperature were monitored during CPB. Patients were divided into two groups according to neural cognitive function scores to explore the relationship between postoperative delayed neurocognitive recovery and the real variability of cerebral oxygen saturation, BIS, MAP, and body temperature during CPB. Results of the study Twenty‐seven patients were diagnosed with postoperative delayed neurocognitive recovery. The occurrence of postoperative delayed neurocognitive recovery after surgery was closely related to the large variability of rSO2 during the rewarming phase of CPB (P < .05). Logistic analysis showed that preoperative arrhythmia, a lower level of serum albumin after surgery and greater rSO2 variability during the rewarming phase were risk factors for postoperative delayed neurocognitive recovery (P < .05). In this study, there was no correlation between postoperative delayed neurocognitive recovery and BIS, MAP or body temperature variability (P > .05). Conclusions drawn from the study and clinical implications The real variability of rSO2 during the CPB rewarming phase was related to postoperative delayed neurocognitive recovery in patients who underwent cardiac surgery.

show abstract

Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case–control study

Cited by 19 publications

References 29 publications

Levels of serum S100B are associated with cognitive dysfunction in patients with type 2 diabetes

Levels of serum S100B are associated with cognitive dysfunction in patients with type 2 diabetes

The Value of Brain Structural Magnetic Resonance Imaging Combined with APOE‐‐ε4 Genotype in Early Diagnosis and Disease Progression of Senile Vascular Cognitive Impairment No Dementia

Association between the variability of cerebral oxygen saturation during cardiopulmonary bypass and delayed postoperative neurocognitive recovery in cardiac valve surgical patients: A pilot study

Contact Info

Product

Resources

About